Get started
Work

Supplementary Table S3 from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Year: 2025
Type: supplementary-materials
Abstract: Dostarlimab treatment-related adverse events on trial.
DOI: 10.1158/2767-9764.29267152
Authors: Olga Zamulko, Vidhya Karivedu, Muhammad Kashif Riaz, Ilaina Monroe, Audrey Romano, Rachel Mulanda, Nicky Kurtzweil, Allie Forsythe, Casey L. Allen, Nusrat Harun, Jianmin Pan, Shesh Rai, Dalia El-Gamal, Trisha M. Wise-Draper
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4411157441
Cites:
Cited by:
Related to: 10